查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1513367

全球放射性药物市场：按最终用户、放射性同位素、应用、类型：机会分析和产业预测（2024-2033）

Radiopharmaceuticals Market By End User, By Radioisotope, By Application, By Type : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 500 Pages | 商品交期: 2-3个工作天内

价格
2023年全球放射性药物市场规模预计为79亿美元，预计2033年将达218亿美元，2024年至2033年复合年增长率为10.6%。放射性药物是含有放射性化学元素（称为放射性同位素）的药物。根据辐射类型，放射性同位素用于诊断和治疗各种疾病。其用途范围从测试和治疗大脑、心臟、肾臟和骨骼等各种器官到治疗癌症和甲状腺功能亢进。放射性药物透过注射或口服给予患者，并可使用外部医疗设备和测试进行监测和分析。大多数国家都制定了专门的安全措施，以保护患者和医护人员免受这些药物的潜在不良影响。
放射性药物市场-IMG1
放射性药物市场主要由慢性病的增加、技术进步以及诊断和治疗过程中应用的扩大所推动。随着癌症、心血管疾病和神经系统疾病等慢性病的盛行率持续上升，对有效诊断工具和标靶治疗的需求不断增长。放射性药物可以提供精确的影像和治疗方案，越来越多地被认为是对抗这些疾病的宝贵工具。此外，PET和SPECT等诊断影像技术的进步显着提高了诊断准确性和效率，可以更早检测和更好地管理疾病，这也推动了市场成长。此外，个人化医疗方法的出现正在推动对放射性药物的需求，因为它们可以根据个别患者的特征和分子标靶进行客製化治疗。然而，开发和生产放射性药物的成本很高，阻碍了市场的成长。这包括与研究、临床试验、製造流程和监管合规相关的成本。此外，放射性药物的复杂性需要专门的基础设施和专业知识，进一步增加了财务负担。相较之下，放射性药物研发活动正在考虑用于治疗诊断学等领域，将诊断影像与标靶治疗相结合，为市场成长提供了机会。放射性药物市场按类型、应用、放射性同位素、最终用户和地区进行细分。按类型划分，市场分为诊断市场和治疗市场。根据应用，它们分为癌症、循环系统和其他。癌症领域又分为摄护腺癌、乳癌、胃肠癌、肺癌、脑肿瘤等。其他部分进一步分为神经学应用和其他应用。在放射性同位素的基础上，市场分为碘I、镓-68、Technetium-99m、氟-18、铜-64、锶-89、钇-90、镭-223、锕-225、镏-177、铜-67，铽-161，锆-89，其他的就完成了。依最终用户划分，市场分为医院/诊所、医学影像中心等。按地区划分，包括北美（美国、加拿大）、欧洲（德国、英国、西班牙、义大利其他欧洲国家）、亚太地区（印度、中国、澳洲、日本、韩国、泰国、马来西亚、印尼、新加坡和台湾） 、中国和亚太其他地区）以及拉丁美洲、中东和非洲（巴西、拉丁美洲其他地区、中东和非洲）。全球放射性药物市场的主要企业包括拜耳公司、康德乐、礼来公司、Bracco、Isotopia Molecular Imaging Ltd.、Actinium Pharmaceuticals, Inc.、诺华公司、Curium Pharma、Nippon Mediphysicals Co., Ltd.、Jubilant Pharmics Co. Ltd、Jubilant Pharmova Limited、Eckert & Ziegler、NorthStar Radioisotopes、国家原子能公司ROSATOM、SOFIE、Lantheus、Telix Pharmaceuticals Limited、Clarity Pharmaceuticals、Fusion Pharmaceuticals Inc.、PRECIRIX、ITM Isotope Technologies Munceuticals、Fusion Pharmaceuticals Inc.、PRECIRIX、ITM Isotope Technologies Munich SE . Necsa) 和Eczacibasi。市场上营运的主要公司正在寻求协议、收购、扩张、临床试验、产品核可、产品升级、合约、产品开发、联盟、地理扩张和合资企业作为扩大产品系列。

相关人员的主要利益

  • 本报告定量分析了 2023 年至 2033 年放射性药物市场分析的细分市场、当前趋势、估计趋势和动态，并确定了一般放射性药物市场的机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商-买家网路的力量。
  • 对放射性药物市场细分的详细分析有助于识别市场机会。
  • 我们根据每个地区的主要国家对全球市场的收益贡献绘製了地图。
  • 市场公司定位有助于基准化分析并提供对市场公司当前地位的清晰了解。
  • 该报告包括对区域和全球放射性药物市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 慢性病增加
      • 主要企业更多采用策略
      • 增加研发活动
    • 抑制因素
      • 开发引进放射性药物的成本高昂
    • 机会
      • 研发线产品增加

第四章放射性药物市场：依最终使用者分类

  • 概述
  • 医院/诊所
  • 医学影像中心
  • 其他的

第五章放射性药物市场：依放射性同位素分类

  • 概述
  • Technetium99m
  • 镓68
  • 碘I
  • 氟18
  • 铜64
  • 锶89
  • 钇90
  • 镭223
  • 锕225
  • 镏177
  • 铜67
  • 铽161
  • 锆89
  • 其他的

第六章 放射性药物市场：依应用分类

  • 概述
  • 癌症
    • 癌症放射性药物市场：依类型
  • 循环系统
  • 其他的
    • 其他放射性药物市场：依类型

第七章放射性药物市场：依类型

  • 概述
  • 诊断
  • 治疗性的

第八章放射性药物市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 新加坡
    • 台湾
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 其他的

第9章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第十章 公司简介

  • Bayer AG
  • Cardinal Health
  • Curium Pharma
  • Eli Lilly and Company
  • Jubilant Pharmova Limited
  • Lantheus
  • ITM Isotope Technologies Munich SE
  • Telix Pharmaceuticals Limited
  • Eckert & Ziegler
  • Bracco
  • South African Nuclear Energy Corporation（NECSA）
  • NorthStar Medical Radioisotopes
  • The State Atomic Energy Corporation ROSATOM
  • SOFIE
  • Isotopia Molecular Imaging
  • Fusion Pharmaceuticals Inc.
  • Clarity Pharmaceuticals
  • Actinium Pharmaceuticals, Inc.
  • PRECIRIX
  • Novartis AG
  • Nihon Medi-Physics Co. Ltd
  • GE Healthcare
  • Eczacibasi
Product Code: A14458
The radiopharmaceuticals market was valued at $7.9 billion in 2023 and is estimated to reach $21.8 billion by 2033, exhibiting a CAGR of 10.6% from 2024 to 2033. Radiopharmaceuticals are medications that include radioactive versions of chemical elements known as radioisotopes. Depending on the type of radiation they emit, radioisotopes can be used to diagnose or treat a variety of medical diseases. Their uses range from examining and treating various organs, including the brain, heart, kidney, and bone, to the treatment of cancer and hyperthyroidism. Radiopharmaceuticals are administered to patients via injection or orally, and they may be monitored and analyzed using external medical equipment and testing. Most nations have specialized safety measures in place to safeguard patients and health workers from the potential harmful effects of these pharmaceuticals.
Radiopharmaceuticals Market - IMG1
The radiopharmaceuticals market is primarily driven by the increase in prevalence of chronic diseases, rise in technological advancements, and growth in applications in diagnostic and therapeutic procedures. As the prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, there is a growing demand for effective diagnostic tools and targeted treatments. Radiopharmaceuticals, with their ability to provide precise imaging and therapeutic options, are increasingly recognized as valuable tools in the fight against these diseases. In addition, advancements in imaging techniques such as PET and SPECT have significantly improved the accuracy and efficiency of diagnosis, enabling early detection and better management of diseases propels the market growth. Additionally, the emergence of personalized medicine approaches has fueled the demand for radiopharmaceuticals, as they allow for tailored treatments on the basis of individual patient characteristics and molecular targets. However, the high cost associated with the development and production of radiopharmaceuticals can be prohibitive, thus hindering the market growth. This includes expenses related to research, clinical trials, and manufacturing processes, and regulatory compliance. The complex nature of radiopharmaceuticals also requires specialized infrastructure and expertise, further adding to the financial burden. In contrast, ongoing R&D activities for radiopharmaceuticals are increasingly being explored for use in areas such as theranostics, which involves combining diagnostic imaging with targeted therapy that provides lucrative opportunities for the market growth. The radiopharmaceuticals market is segmented on the basis of type, application, radioisotope, end user, and region. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of application, the market is classified into cancer, cardiology and others. The cancer segment is further classified into prostate cancer, breast cancer, gastrointestinal cancer, lung cancer, brain tumors, and others. The others segment further bifurcated into Neurological Applications and other applications. On the basis of radioisotope, the market is classified into Iodine I, Gallium 68, Technetium 99m, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, and others. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. On the basis of region, the market is studied across North America (U.S. and Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, Thailand, Malaysia, Indonesia, Singapore, Taiwan, Province Of China, and Rest of Asia-Pacific), and LAMEA (Brazil and Rest of LAMEA). Major key players that operate in the global radiopharmaceuticals market are Bayer AG, Cardinal Health, Eli Lilly and Company, Bracco, Isotopia Molecular Imaging Ltd., Actinium Pharmaceuticals, Inc., Novartis AG, Curium Pharma, Nihon Medi-Physics Co. Ltd., Jubilant Pharmova Limited, Eckert & Ziegler, NorthStar Radioisotopes, The State Atomic Energy Corporation ROSATOM, SOFIE, Lantheus, Telix Pharmaceuticals Limited, Clarity Pharmaceuticals, Fusion Pharmaceuticals Inc., PRECIRIX, ITM Isotope Technologies Munich SE, GE Healthcare, South African Nuclear Energy Corporation (Necsa), and Eczacibasi. Key players operating in the market have adopted agreement, acquisition, expansion, clinical trial, product approval, product upgrade, contract, product development, collaboration, geographical expansion, joint venture, and expansion, as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2023 to 2033 to identify the prevailing radiopharmaceuticals market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By End User

  • Hospitals and Clinics
  • Medical Imaging Centers
  • Others

By Radioisotope

  • Technetium 99m
  • Gallium 68
  • Iodine I
  • Fluorine 18
  • Copper 64
  • Strontium 89
  • Yttrium 90
  • Radium 223
  • Actinium 225
  • Lutetium 177
  • Copper 67
  • Terbium 161
  • Zirconium 89
  • Others

By Application

  • Cancer
    • Type
    • Prostate Cancer
    • Breast Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Brain Tumors
    • Others
  • Cardiology
  • Others
    • Type
    • Neurological Applications
    • Other Applications

By Type

  • Diagnostic
  • Therapeutic

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
    • Malaysia
    • Indonesia
    • Singapore
    • Taiwan, Province Of China
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Rest of LAMEA

Key Market Players:

    • Cardinal Health
    • Eli Lilly and Company
    • Novartis AG
    • Jubilant Pharmova Limited
    • The State Atomic Energy Corporation ROSATOM
    • SOFIE
    • Telix Pharmaceuticals Limited
    • Clarity Pharmaceuticals
    • PRECIRIX
    • NorthStar Medical Radioisotopes
    • South African Nuclear Energy Corporation (Necsa)
    • Bayer AG
    • Bracco
    • Curium Pharma
    • Eckert & Ziegler
    • Lantheus
    • Nihon Medi-Physics Co. Ltd
    • Isotopia Molecular Imaging
    • ITM Isotope Technologies Munich SE
    • GE Healthcare
    • Actinium Pharmaceuticals, Inc.
    • Fusion Pharmaceuticals Inc.
    • Eczacibasi

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate low threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. High intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of chronic diseases
      • 3.4.1.2. Rise in adoption of strategies by key players
      • 3.4.1.3. Rise in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of development and implementation of radiopharmaceuticals
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in number of pipeline products

CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY END USER

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hospitals and Clinics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Medical Imaging Centers
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Technetium 99m
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Gallium 68
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Iodine I
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Fluorine 18
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Copper 64
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Strontium 89
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Yttrium 90
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country
  • 5.9. Radium 223
    • 5.9.1. Key market trends, growth factors and opportunities
    • 5.9.2. Market size and forecast, by region
    • 5.9.3. Market share analysis by country
  • 5.10. Actinium 225
    • 5.10.1. Key market trends, growth factors and opportunities
    • 5.10.2. Market size and forecast, by region
    • 5.10.3. Market share analysis by country
  • 5.11. Lutetium 177
    • 5.11.1. Key market trends, growth factors and opportunities
    • 5.11.2. Market size and forecast, by region
    • 5.11.3. Market share analysis by country
  • 5.12. Copper 67
    • 5.12.1. Key market trends, growth factors and opportunities
    • 5.12.2. Market size and forecast, by region
    • 5.12.3. Market share analysis by country
  • 5.13. Terbium 161
    • 5.13.1. Key market trends, growth factors and opportunities
    • 5.13.2. Market size and forecast, by region
    • 5.13.3. Market share analysis by country
  • 5.14. Zirconium 89
    • 5.14.1. Key market trends, growth factors and opportunities
    • 5.14.2. Market size and forecast, by region
    • 5.14.3. Market share analysis by country
  • 5.15. Others
    • 5.15.1. Key market trends, growth factors and opportunities
    • 5.15.2. Market size and forecast, by region
    • 5.15.3. Market share analysis by country

CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Cancer
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
    • 6.2.4. Cancer Radiopharmaceuticals Market by Type
  • 6.3. Cardiology
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
    • 6.4.4. Others Radiopharmaceuticals Market by Type

CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Diagnostic
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Therapeutic
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country

CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by End User
    • 8.2.3. Market size and forecast, by Radioisotope
    • 8.2.4. Market size and forecast, by Application
    • 8.2.5. Market size and forecast, by Type
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by End User
      • 8.2.6.1.2. Market size and forecast, by Radioisotope
      • 8.2.6.1.3. Market size and forecast, by Application
      • 8.2.6.1.4. Market size and forecast, by Type
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by End User
      • 8.2.6.2.2. Market size and forecast, by Radioisotope
      • 8.2.6.2.3. Market size and forecast, by Application
      • 8.2.6.2.4. Market size and forecast, by Type
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by End User
    • 8.3.3. Market size and forecast, by Radioisotope
    • 8.3.4. Market size and forecast, by Application
    • 8.3.5. Market size and forecast, by Type
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by End User
      • 8.3.6.1.2. Market size and forecast, by Radioisotope
      • 8.3.6.1.3. Market size and forecast, by Application
      • 8.3.6.1.4. Market size and forecast, by Type
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by End User
      • 8.3.6.2.2. Market size and forecast, by Radioisotope
      • 8.3.6.2.3. Market size and forecast, by Application
      • 8.3.6.2.4. Market size and forecast, by Type
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by End User
      • 8.3.6.3.2. Market size and forecast, by Radioisotope
      • 8.3.6.3.3. Market size and forecast, by Application
      • 8.3.6.3.4. Market size and forecast, by Type
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by End User
      • 8.3.6.4.2. Market size and forecast, by Radioisotope
      • 8.3.6.4.3. Market size and forecast, by Application
      • 8.3.6.4.4. Market size and forecast, by Type
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by End User
      • 8.3.6.5.2. Market size and forecast, by Radioisotope
      • 8.3.6.5.3. Market size and forecast, by Application
      • 8.3.6.5.4. Market size and forecast, by Type
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by End User
      • 8.3.6.6.2. Market size and forecast, by Radioisotope
      • 8.3.6.6.3. Market size and forecast, by Application
      • 8.3.6.6.4. Market size and forecast, by Type
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by End User
    • 8.4.3. Market size and forecast, by Radioisotope
    • 8.4.4. Market size and forecast, by Application
    • 8.4.5. Market size and forecast, by Type
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by End User
      • 8.4.6.1.2. Market size and forecast, by Radioisotope
      • 8.4.6.1.3. Market size and forecast, by Application
      • 8.4.6.1.4. Market size and forecast, by Type
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by End User
      • 8.4.6.2.2. Market size and forecast, by Radioisotope
      • 8.4.6.2.3. Market size and forecast, by Application
      • 8.4.6.2.4. Market size and forecast, by Type
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by End User
      • 8.4.6.3.2. Market size and forecast, by Radioisotope
      • 8.4.6.3.3. Market size and forecast, by Application
      • 8.4.6.3.4. Market size and forecast, by Type
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by End User
      • 8.4.6.4.2. Market size and forecast, by Radioisotope
      • 8.4.6.4.3. Market size and forecast, by Application
      • 8.4.6.4.4. Market size and forecast, by Type
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by End User
      • 8.4.6.5.2. Market size and forecast, by Radioisotope
      • 8.4.6.5.3. Market size and forecast, by Application
      • 8.4.6.5.4. Market size and forecast, by Type
      • 8.4.6.6. Thailand
      • 8.4.6.6.1. Market size and forecast, by End User
      • 8.4.6.6.2. Market size and forecast, by Radioisotope
      • 8.4.6.6.3. Market size and forecast, by Application
      • 8.4.6.6.4. Market size and forecast, by Type
      • 8.4.6.7. Malaysia
      • 8.4.6.7.1. Market size and forecast, by End User
      • 8.4.6.7.2. Market size and forecast, by Radioisotope
      • 8.4.6.7.3. Market size and forecast, by Application
      • 8.4.6.7.4. Market size and forecast, by Type
      • 8.4.6.8. Indonesia
      • 8.4.6.8.1. Market size and forecast, by End User
      • 8.4.6.8.2. Market size and forecast, by Radioisotope
      • 8.4.6.8.3. Market size and forecast, by Application
      • 8.4.6.8.4. Market size and forecast, by Type
      • 8.4.6.9. Singapore
      • 8.4.6.9.1. Market size and forecast, by End User
      • 8.4.6.9.2. Market size and forecast, by Radioisotope
      • 8.4.6.9.3. Market size and forecast, by Application
      • 8.4.6.9.4. Market size and forecast, by Type
      • 8.4.6.10. Taiwan, Province Of China
      • 8.4.6.10.1. Market size and forecast, by End User
      • 8.4.6.10.2. Market size and forecast, by Radioisotope
      • 8.4.6.10.3. Market size and forecast, by Application
      • 8.4.6.10.4. Market size and forecast, by Type
      • 8.4.6.11. Rest of Asia-Pacific
      • 8.4.6.11.1. Market size and forecast, by End User
      • 8.4.6.11.2. Market size and forecast, by Radioisotope
      • 8.4.6.11.3. Market size and forecast, by Application
      • 8.4.6.11.4. Market size and forecast, by Type
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by End User
    • 8.5.3. Market size and forecast, by Radioisotope
    • 8.5.4. Market size and forecast, by Application
    • 8.5.5. Market size and forecast, by Type
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by End User
      • 8.5.6.1.2. Market size and forecast, by Radioisotope
      • 8.5.6.1.3. Market size and forecast, by Application
      • 8.5.6.1.4. Market size and forecast, by Type
      • 8.5.6.2. Rest of LAMEA
      • 8.5.6.2.1. Market size and forecast, by End User
      • 8.5.6.2.2. Market size and forecast, by Radioisotope
      • 8.5.6.2.3. Market size and forecast, by Application
      • 8.5.6.2.4. Market size and forecast, by Type

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Bayer AG
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
    • 10.1.7. Key strategic moves and developments
  • 10.2. Cardinal Health
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. Curium Pharma
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Key strategic moves and developments
  • 10.4. Eli Lilly and Company
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
    • 10.4.7. Key strategic moves and developments
  • 10.5. Jubilant Pharmova Limited
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
    • 10.5.7. Key strategic moves and developments
  • 10.6. Lantheus
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
    • 10.6.7. Key strategic moves and developments
  • 10.7. ITM Isotope Technologies Munich SE
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Key strategic moves and developments
  • 10.8. Telix Pharmaceuticals Limited
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. Eckert & Ziegler
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.7. Key strategic moves and developments
  • 10.10. Bracco
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Key strategic moves and developments
  • 10.11. South African Nuclear Energy Corporation (NECSA)
    • 10.11.1. Company overview
    • 10.11.2. Key executives
    • 10.11.3. Company snapshot
    • 10.11.4. Operating business segments
    • 10.11.5. Product portfolio
    • 10.11.6. Business performance
    • 10.11.7. Key strategic moves and developments
  • 10.12. NorthStar Medical Radioisotopes
    • 10.12.1. Company overview
    • 10.12.2. Key executives
    • 10.12.3. Company snapshot
    • 10.12.4. Operating business segments
    • 10.12.5. Product portfolio
    • 10.12.6. Key strategic moves and developments
  • 10.13. The State Atomic Energy Corporation ROSATOM
    • 10.13.1. Company overview
    • 10.13.2. Key executives
    • 10.13.3. Company snapshot
    • 10.13.4. Operating business segments
    • 10.13.5. Product portfolio
    • 10.13.6. Key strategic moves and developments
  • 10.14. SOFIE
    • 10.14.1. Company overview
    • 10.14.2. Key executives
    • 10.14.3. Company snapshot
    • 10.14.4. Operating business segments
    • 10.14.5. Product portfolio
    • 10.14.6. Key strategic moves and developments
  • 10.15. Isotopia Molecular Imaging
    • 10.15.1. Company overview
    • 10.15.2. Key executives
    • 10.15.3. Company snapshot
    • 10.15.4. Operating business segments
    • 10.15.5. Product portfolio
    • 10.15.6. Key strategic moves and developments
  • 10.16. Fusion Pharmaceuticals Inc.
    • 10.16.1. Company overview
    • 10.16.2. Key executives
    • 10.16.3. Company snapshot
    • 10.16.4. Operating business segments
    • 10.16.5. Product portfolio
    • 10.16.6. Key strategic moves and developments
  • 10.17. Clarity Pharmaceuticals
    • 10.17.1. Company overview
    • 10.17.2. Key executives
    • 10.17.3. Company snapshot
    • 10.17.4. Operating business segments
    • 10.17.5. Product portfolio
    • 10.17.6. Key strategic moves and developments
  • 10.18. Actinium Pharmaceuticals, Inc.
    • 10.18.1. Company overview
    • 10.18.2. Key executives
    • 10.18.3. Company snapshot
    • 10.18.4. Operating business segments
    • 10.18.5. Product portfolio
    • 10.18.6. Business performance
    • 10.18.7. Key strategic moves and developments
  • 10.19. PRECIRIX
    • 10.19.1. Company overview
    • 10.19.2. Key executives
    • 10.19.3. Company snapshot
    • 10.19.4. Operating business segments
    • 10.19.5. Product portfolio
    • 10.19.6. Key strategic moves and developments
  • 10.20. Novartis AG
    • 10.20.1. Company overview
    • 10.20.2. Key executives
    • 10.20.3. Company snapshot
    • 10.20.4. Operating business segments
    • 10.20.5. Product portfolio
    • 10.20.6. Business performance
    • 10.20.7. Key strategic moves and developments
  • 10.21. Nihon Medi-Physics Co. Ltd
    • 10.21.1. Company overview
    • 10.21.2. Key executives
    • 10.21.3. Company snapshot
    • 10.21.4. Operating business segments
    • 10.21.5. Product portfolio
  • 10.22. GE Healthcare
    • 10.22.1. Company overview
    • 10.22.2. Key executives
    • 10.22.3. Company snapshot
    • 10.22.4. Operating business segments
    • 10.22.5. Product portfolio
    • 10.22.6. Business performance
    • 10.22.7. Key strategic moves and developments
  • 10.23. Eczacibasi
    • 10.23.1. Company overview
    • 10.23.2. Key executives
    • 10.23.3. Company snapshot
    • 10.23.4. Operating business segments
    • 10.23.5. Product portfolio
    • 10.23.6. Business performance
    • 10.23.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 02. RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 06. RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY REGION, 2023-2033 ($MILLION)
  • TABLE 07. RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY REGION, 2023-2033 ($MILLION)
  • TABLE 08. RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY REGION, 2023-2033 ($MILLION)
  • TABLE 09. RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY REGION, 2023-2033 ($MILLION)
  • TABLE 10. RADIOPHARMACEUTICALS MARKET FOR COPPER 64, BY REGION, 2023-2033 ($MILLION)
  • TABLE 11. RADIOPHARMACEUTICALS MARKET FOR STRONTIUM 89, BY REGION, 2023-2033 ($MILLION)
  • TABLE 12. RADIOPHARMACEUTICALS MARKET FOR YTTRIUM 90, BY REGION, 2023-2033 ($MILLION)
  • TABLE 13. RADIOPHARMACEUTICALS MARKET FOR RADIUM 223, BY REGION, 2023-2033 ($MILLION)
  • TABLE 14. RADIOPHARMACEUTICALS MARKET FOR ACTINIUM 225, BY REGION, 2023-2033 ($MILLION)
  • TABLE 15. RADIOPHARMACEUTICALS MARKET FOR LUTETIUM 177, BY REGION, 2023-2033 ($MILLION)
  • TABLE 16. RADIOPHARMACEUTICALS MARKET FOR COPPER 67, BY REGION, 2023-2033 ($MILLION)
  • TABLE 17. RADIOPHARMACEUTICALS MARKET FOR TERBIUM 161, BY REGION, 2023-2033 ($MILLION)
  • TABLE 18. RADIOPHARMACEUTICALS MARKET FOR ZIRCONIUM 89, BY REGION, 2023-2033 ($MILLION)
  • TABLE 19. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 21. RADIOPHARMACEUTICALS MARKET FOR CANCER, BY REGION, 2023-2033 ($MILLION)
  • TABLE 22. GLOBAL CANCER RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 23. RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY REGION, 2023-2033 ($MILLION)
  • TABLE 24. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 25. GLOBAL OTHERS RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 27. RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY REGION, 2023-2033 ($MILLION)
  • TABLE 28. RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY REGION, 2023-2033 ($MILLION)
  • TABLE 29. RADIOPHARMACEUTICALS MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 30. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 31. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 32. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 33. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 34. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 35. U.S. RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 36. U.S. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 37. U.S. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 38. U.S. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 39. CANADA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 40. CANADA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 41. CANADA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 42. CANADA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 43. EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 44. EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 45. EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 46. EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 47. EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 48. GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 49. GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 50. GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 51. GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 52. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 53. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 54. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 55. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 56. UK RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 57. UK RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 58. UK RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 59. UK RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 60. ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 61. ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 62. ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 63. ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 64. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 65. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 66. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 67. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 68. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 69. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 70. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 71. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 72. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 73. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 74. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 75. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 76. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 77. JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 78. JAPAN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 79. JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 80. JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 81. CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 82. CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 83. CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 84. CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 85. INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 86. INDIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 87. INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 88. INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 89. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 90. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 91. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 92. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 93. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 94. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 95. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 96. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 97. THAILAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 98. THAILAND RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 99. THAILAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 100. THAILAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 101. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 102. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 103. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 104. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 105. INDONESIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 106. INDONESIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 107. INDONESIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 108. INDONESIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 109. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 110. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 111. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 112. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 113. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 114. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 115. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 116. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 117. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 118. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 119. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 120. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 121. LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 122. LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 123. LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 124. LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 125. LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 126. BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 127. BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 128. BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 129. BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 130. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 131. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 132. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 133. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 134. BAYER AG: KEY EXECUTIVES
  • TABLE 135. BAYER AG: COMPANY SNAPSHOT
  • TABLE 136. BAYER AG: PRODUCT SEGMENTS
  • TABLE 137. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 138. BAYER AG: KEY STRATEGIES
  • TABLE 139. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 140. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 141. CARDINAL HEALTH: PRODUCT SEGMENTS
  • TABLE 142. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 143. CARDINAL HEALTH: KEY STRATEGIES
  • TABLE 144. CURIUM PHARMA: KEY EXECUTIVES
  • TABLE 145. CURIUM PHARMA: COMPANY SNAPSHOT
  • TABLE 146. CURIUM PHARMA: PRODUCT SEGMENTS
  • TABLE 147. CURIUM PHARMA: PRODUCT PORTFOLIO
  • TABLE 148. CURIUM PHARMA: KEY STRATEGIES
  • TABLE 149. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 150. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 151. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 152. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 153. ELI LILLY AND COMPANY: KEY STRATEGIES
  • TABLE 154. JUBILANT PHARMOVA LIMITED: KEY EXECUTIVES
  • TABLE 155. JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT
  • TABLE 156. JUBILANT PHARMOVA LIMITED: PRODUCT SEGMENTS
  • TABLE 157. JUBILANT PHARMOVA LIMITED: PRODUCT PORTFOLIO
  • TABLE 158. JUBILANT PHARMOVA LIMITED: KEY STRATEGIES
  • TABLE 159. LANTHEUS: KEY EXECUTIVES
  • TABLE 160. LANTHEUS: COMPANY SNAPSHOT
  • TABLE 161. LANTHEUS: PRODUCT SEGMENTS
  • TABLE 162. LANTHEUS: PRODUCT PORTFOLIO
  • TABLE 163. LANTHEUS: KEY STRATEGIES
  • TABLE 164. ITM ISOTOPE TECHNOLOGIES MUNICH SE: KEY EXECUTIVES
  • TABLE 165. ITM ISOTOPE TECHNOLOGIES MUNICH SE: COMPANY SNAPSHOT
  • TABLE 166. ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCT SEGMENTS
  • TABLE 167. ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCT PORTFOLIO
  • TABLE 168. ITM ISOTOPE TECHNOLOGIES MUNICH SE: KEY STRATEGIES
  • TABLE 169. TELIX PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 170. TELIX PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 171. TELIX PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 172. TELIX PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 173. TELIX PHARMACEUTICALS LIMITED: KEY STRATEGIES
  • TABLE 174. ECKERT & ZIEGLER: KEY EXECUTIVES
  • TABLE 175. ECKERT & ZIEGLER: COMPANY SNAPSHOT
  • TABLE 176. ECKERT & ZIEGLER: PRODUCT SEGMENTS
  • TABLE 177. ECKERT & ZIEGLER: PRODUCT PORTFOLIO
  • TABLE 178. ECKERT & ZIEGLER: KEY STRATEGIES
  • TABLE 179. BRACCO: KEY EXECUTIVES
  • TABLE 180. BRACCO: COMPANY SNAPSHOT
  • TABLE 181. BRACCO: PRODUCT SEGMENTS
  • TABLE 182. BRACCO: PRODUCT PORTFOLIO
  • TABLE 183. BRACCO: KEY STRATEGIES
  • TABLE 184. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): KEY EXECUTIVES
  • TABLE 185. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): COMPANY SNAPSHOT
  • TABLE 186. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): PRODUCT SEGMENTS
  • TABLE 187. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): PRODUCT PORTFOLIO
  • TABLE 188. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): KEY STRATEGIES
  • TABLE 189. NORTHSTAR MEDICAL RADIOISOTOPES: KEY EXECUTIVES
  • TABLE 190. NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY SNAPSHOT
  • TABLE 191. NORTHSTAR MEDICAL RADIOISOTOPES: PRODUCT SEGMENTS
  • TABLE 192. NORTHSTAR MEDICAL RADIOISOTOPES: PRODUCT PORTFOLIO
  • TABLE 193. NORTHSTAR MEDICAL RADIOISOTOPES: KEY STRATEGIES
  • TABLE 194. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: KEY EXECUTIVES
  • TABLE 195. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: COMPANY SNAPSHOT
  • TABLE 196. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: PRODUCT SEGMENTS
  • TABLE 197. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: PRODUCT PORTFOLIO
  • TABLE 198. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: KEY STRATEGIES
  • TABLE 199. SOFIE: KEY EXECUTIVES
  • TABLE 200. SOFIE: COMPANY SNAPSHOT
  • TABLE 201. SOFIE: PRODUCT SEGMENTS
  • TABLE 202. SOFIE: PRODUCT PORTFOLIO
  • TABLE 203. SOFIE: KEY STRATEGIES
  • TABLE 204. ISOTOPIA MOLECULAR IMAGING: KEY EXECUTIVES
  • TABLE 205. ISOTOPIA MOLECULAR IMAGING: COMPANY SNAPSHOT
  • TABLE 206. ISOTOPIA MOLECULAR IMAGING: PRODUCT SEGMENTS
  • TABLE 207. ISOTOPIA MOLECULAR IMAGING: PRODUCT PORTFOLIO
  • TABLE 208. ISOTOPIA MOLECULAR IMAGING: KEY STRATEGIES
  • TABLE 209. FUSION PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 210. FUSION PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 211. FUSION PHARMACEUTICALS INC.: PRODUCT SEGMENTS
  • TABLE 212. FUSION PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 213. FUSION PHARMACEUTICALS INC.: KEY STRATEGIES
  • TABLE 214. CLARITY PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 215. CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 216. CLARITY PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 217. CLARITY PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 218. CLARITY PHARMACEUTICALS: KEY STRATEGIES
  • TABLE 219. ACTINIUM PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 220. ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 221. ACTINIUM PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 222. ACTINIUM PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 223. ACTINIUM PHARMACEUTICALS, INC.: KEY STRATEGIES
  • TABLE 224. PRECIRIX: KEY EXECUTIVES
  • TABLE 225. PRECIRIX: COMPANY SNAPSHOT
  • TABLE 226. PRECIRIX: PRODUCT SEGMENTS
  • TABLE 227. PRECIRIX: PRODUCT PORTFOLIO
  • TABLE 228. PRECIRIX: KEY STRATEGIES
  • TABLE 229. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 230. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 231. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 232. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 233. NOVARTIS AG: KEY STRATEGIES
  • TABLE 234. NIHON MEDI-PHYSICS CO. LTD: KEY EXECUTIVES
  • TABLE 235. NIHON MEDI-PHYSICS CO. LTD: COMPANY SNAPSHOT
  • TABLE 236. NIHON MEDI-PHYSICS CO. LTD: PRODUCT SEGMENTS
  • TABLE 237. NIHON MEDI-PHYSICS CO. LTD: PRODUCT PORTFOLIO
  • TABLE 238. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 239. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 240. GE HEALTHCARE: PRODUCT SEGMENTS
  • TABLE 241. GE HEALTHCARE: SERVICE SEGMENTS
  • TABLE 242. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 243. GE HEALTHCARE: KEY STRATEGIES
  • TABLE 244. ECZACIBASI: KEY EXECUTIVES
  • TABLE 245. ECZACIBASI: COMPANY SNAPSHOT
  • TABLE 246. ECZACIBASI: PRODUCT SEGMENTS
  • TABLE 247. ECZACIBASI: PRODUCT PORTFOLIO
  • TABLE 248. ECZACIBASI: KEY STRATEGIES

LIST OF FIGURES

  • FIGURE 01. RADIOPHARMACEUTICALS MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF RADIOPHARMACEUTICALS MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN RADIOPHARMACEUTICALS MARKET (2023 TO 2033)
  • FIGURE 04. TOP INVESTMENT POCKETS IN RADIOPHARMACEUTICALS MARKET (2024-2033)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. RADIOPHARMACEUTICALS MARKET, BY END USER, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023 AND 2033(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR COPPER 64, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR STRONTIUM 89, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR YTTRIUM 90, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR RADIUM 223, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR ACTINIUM 225, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR LUTETIUM 177, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR COPPER 67, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR TERBIUM 161, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR ZIRCONIUM 89, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 30. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023 AND 2033(%)
  • FIGURE 31. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR CANCER, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 32. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 33. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 34. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023 AND 2033(%)
  • FIGURE 35. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 36. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 37. RADIOPHARMACEUTICALS MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 38. U.S. RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 39. CANADA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 40. GERMANY RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 41. FRANCE RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 42. UK RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 43. ITALY RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 44. SPAIN RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 45. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 46. JAPAN RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 47. CHINA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 48. INDIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 49. AUSTRALIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 50. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 51. THAILAND RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 52. MALAYSIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 53. INDONESIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 54. SINGAPORE RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 55. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 56. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 57. BRAZIL RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 58. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 59. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
  • FIGURE 60. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
  • FIGURE 61. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
  • FIGURE 62. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 63. COMPETITIVE DASHBOARD
  • FIGURE 64. COMPETITIVE HEATMAP: RADIOPHARMACEUTICALS MARKET
  • FIGURE 65. TOP PLAYER POSITIONING, 2023
  • FIGURE 66. BAYER AG: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 67. BAYER AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2021-2023 ($MILLION)
  • FIGURE 68. BAYER AG: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 69. BAYER AG: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 70. CARDINAL HEALTH: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 71. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 72. CARDINAL HEALTH: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 73. ELI LILLY AND COMPANY: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 74. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 75. JUBILANT PHARMOVA LIMITED: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 76. JUBILANT PHARMOVA LIMITED: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 77. JUBILANT PHARMOVA LIMITED: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 78. LANTHEUS: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 79. LANTHEUS: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 80. TELIX PHARMACEUTICALS LIMITED: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 81. TELIX PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 82. ECKERT & ZIEGLER: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 83. ECKERT & ZIEGLER: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 84. ECKERT & ZIEGLER: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 85. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 86. ACTINIUM PHARMACEUTICALS, INC.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 87. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 88. NOVARTIS AG: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 89. GE HEALTHCARE: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 90. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 91. GE HEALTHCARE: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 92. ECZACIBASI: NET REVENUE, 2020-2022 ($MILLION)